Masimo Co. (NASDAQ:MASI) Given Consensus Rating of “Moderate Buy” by Brokerages

Masimo Co. (NASDAQ:MASI) has received a consensus rating of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $194.80.

Several research analysts recently weighed in on MASI shares. Stifel Nicolaus reissued a “buy” rating and set a $190.00 price target (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Raymond James upped their price target on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th. Wells Fargo & Company upped their target price on Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research report on Wednesday, February 26th. Finally, Piper Sandler upped their target price on Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th.

Masimo Trading Up 1.5 %

Shares of Masimo stock opened at $168.21 on Monday. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The firm has a market cap of $9.07 billion, a price-to-earnings ratio of 116.01 and a beta of 1.03. The business has a fifty day simple moving average of $174.84 and a 200-day simple moving average of $157.94. Masimo has a fifty-two week low of $101.61 and a fifty-two week high of $194.88.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, beating the consensus estimate of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business had revenue of $600.70 million during the quarter, compared to the consensus estimate of $593.35 million. On average, equities analysts forecast that Masimo will post 4.1 EPS for the current fiscal year.

Insider Activity

In related news, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the sale, the director now owns 16,581 shares in the company, valued at $2,754,601.53. This represents a 11.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Bilal Muhsin sold 30,000 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the sale, the chief operating officer now owns 24,172 shares of the company’s stock, valued at approximately $4,048,568.28. The trade was a 55.38 % decrease in their position. The disclosure for this sale can be found here. 9.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Masimo

A number of hedge funds have recently modified their holdings of MASI. FMR LLC raised its position in Masimo by 41.2% in the 3rd quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock valued at $900,860,000 after purchasing an additional 1,970,883 shares during the last quarter. Capital Research Global Investors lifted its position in Masimo by 80.5% during the 4th quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider’s stock worth $405,807,000 after buying an additional 1,094,647 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in Masimo by 119.0% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider’s stock worth $286,823,000 after buying an additional 943,001 shares in the last quarter. Alliancebernstein L.P. lifted its position in Masimo by 1,276.9% during the 4th quarter. Alliancebernstein L.P. now owns 947,391 shares of the medical equipment provider’s stock worth $156,604,000 after buying an additional 878,587 shares in the last quarter. Finally, Corient Private Wealth LLC lifted its position in Masimo by 8,847.1% during the 4th quarter. Corient Private Wealth LLC now owns 347,683 shares of the medical equipment provider’s stock worth $57,472,000 after buying an additional 343,797 shares in the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.